Retrospective and prospective study in chronic nonbacterial osteomyelitis of clinic-based multicenter data collection
Active Grant Awarded
- Award ID
- R01FD008230
- Recipient
-
Seattle Children's Hospital UEI SZ32VTCXM799
- Awarding agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Obligated
- $399,599
Award facts
- Assistance listing
- 93.103 Food and Drug Administration Research
- Completion date 4% complete
- Funding agency
- Office of Medical Products and Tobacco Food and Drug Administration, Department of Health and Human Services
- Place of performance
- Seattle, WA 98105, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services Food and Drug Administration awarded Seattle Children's Hospital, doing business as Seattle Children's Research Institute, $399,599 obligated on September 23, 2026, under Food and Drug Administration Research (CFDA 93.103), through Grant R01FD008230. The award funds a retrospective and prospective, clinic-based multicenter study of chronic nonbacterial osteomyelitis (CNO), also known as chronic recurrent multifocal osteomyelitis, a severe autoinflammatory bone disease that predominantly affects children and young adults. Aim 1 determines short-term responses to three major standardized second-line treatments (conventional synthetic disease-modifying anti-rheumatic drugs, tumor necrosis factor inhibitors, and bisphosphonates) and establishes their effect sizes in 150 children with CNO from U.S. sites of the Prospective Chronic Nonbacterial Osteomyelitis International Registry (CHOIR). A second aim assesses long-term skeletal health. Secondary outcomes include a validated composite clinical disease activity score, validated patient-reported outcomes, and a standardized radiographic activity index based on whole-body MRI. The study draws on CHOIR, which has enrolled more than 600 patients, including 500 from ten U.S. sites. The period of performance runs from the September 23, 2026 award date to an ultimate completion date of August 31, 2030, with work performed in Seattle, Washington 98105.
Description
- Abstract
- Chronic nonbacterial osteomyelitis (CNO), also known as chronic recurrent multifocal osteomyelitis (CRMO), is a severe autoinflammatory bone disease of unknown etiology. This disease predominantly affects children and young adults and is associated with debilitating functional impairments, pain and poor quality of life. First-line treatment of CNO is non-steroidal anti-inflammatory drugs (NSAIDS). Patients who fail treatment with NSAIDS and those who have high-risk skeletal site involvement often require second-line treatment with 1) conventional synthetic disease modifying anti-rheumatic drugs (CSDMARD), 2) tumor necrosis factor inhibitors (TNFI), or 3) bisphosphonates. Data from the prospective chronic nonbacterial osteomyelitis international registry (CHOIR) and a survey of practicing pediatric rheumatologists showed widespread use of these second-line therapies, yet the effectiveness of second-line therapies has not been evaluated using a validated outcome measurement. There is a need to 1) assess the efficacies of current standard treatments and 2) determine the impact of these treatments on disease outcome 5 years after diagnosis utilizing CHOIR. CHOIR has enrolled >600 patients, including 500 patients from ten U.S. Sites, which provides a comprehensive data collection and analysis platform for the proposed research. Several disease assessment scores have been proposed including a validated composite clinical disease activity score (CDAS). Other validated patient reported outcomes (PROS) and a standardized radiographic activity index (RAI) based on whole body MRI will be used as secondary outcomes. We propose to 1) determine the short-term responses from 3 major standardized second-line treatments and establish their effect size in 150 children with CNO from U.S. CHOIR sites (aim 1), 2) assess the long-term skeletal health, disease status, growth, and risk of other autoimmune diseases in patients who are treated with only NSAIDS and those who are exposed to second-line treatments for CNO (aim 2). We hypothesize that 1) children with CNO receiving second-line treatments will show improved CDAS, pro and RAI scores and 2) there is a significant increase of skeletal complications, onset of other autoimmune diseases, and growth delay during the first 5 years after diagnosis. The most common skeletal complications will be bony expansion and vertebral height loss. This study will provide critical data to guide the design of an orphan drug trial in this rare, life-changing inflammatory disease.
Quick answers
Who received award R01FD008230?
R01FD008230 was awarded to Seattle Children's Hospital by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 23, 2026.
How much is award R01FD008230 worth?
$399,599 has been obligated on R01FD008230.
Which agency awarded R01FD008230?
FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded R01FD008230, with funding from Office of Medical Products and Tobacco (Food and Drug Administration).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award